Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment

Exclusion Criteria

• •1. Radiographic imaging indicating massive cerebral infarction with corresponding symptoms;
• •2. Required craniotomy or craniotomy with small bone flap to remove SDH;
• •3. Emergency SDH removal/drainage;
• •4. Bilateral SDH with unknown origin of symptoms;
• •5. Anatomical variations that may affect the safety of MMA embolization (e.g., prominent middle MMA-ophthalmic artery anastomosis);
• •6. Intractable coagulation dysfunction or abnormal platelet count and function (pre-operative International Normalized Ratio \[INR\] \> 1.5 and/or platelet count \< 80109/L);
• •7. Contraindications to cerebral angiography, such as allergy to iodinated contrast agents, renal insufficiency (GFR \< 30 ml/min), etc.;
• •8. Computed tomography (CT) or magnetic resonance imaging (MRI) showing intracranial space-occupying lesions;
• •9. Pregnancy or planning to become pregnant;
• •10. Serious or fatal coexisting disease that may prevent improvement of conditions or completion of follow-up;
• •11. Life expectancy \< 1 year;
• •12. Recent operation unrelated to this study or investigators believe that they will be at higher risks if antiplatelet and/or anticoagulant drugs are discontinued;
• •13. Inability to complete follow-up as required by the protocol;
• •14. Patients participating in other clinical trials;
• •15. Prior surgery or interventional therapy on target SDH;
• •16. Inability to complete MMA embolization before trepanation and drainage.